Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advances in Biomarker Sciences and Technology is Scopus-indexed (Q3, CiteScore 3.1), DOAJ. Published by KeAi Publishing Communications Ltd..
Checked against the index lists dated .
ISSN 2543-1064Verify ISSN ↗
Publisher: KeAi Publishing Communications Ltd.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry (medical) | 40 / 78 | 49th | Q3 |
| Clinical Biochemistry | 81 / 124 | 35th | Q3 |
| Molecular Medicine | 135 / 179 | 24th | Q4 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q3, CiteScore 3.1.
Advances in Biomarker Sciences and Technology is Q3 in Biochemistry (medical) (rank 40 of 78), Q3 in Clinical Biochemistry (rank 81 of 124) and Q4 in Molecular Medicine (rank 135 of 179), by CiteScore 2025.
Advances in Biomarker Sciences and Technology is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 3.1, quartile Q3, 49th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.335, quartile Q3, with an H-index of 10.
The publisher lists an article processing charge of about US$700 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advances in Biomarker Sciences and Technology is published by KeAi Publishing Communications Ltd. Its ISSN is 2543-1064.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Advances in Biomarker Sciences and Technology has an h-index of 12 and a 2-year mean of 2.22 citations per paper (OpenAlex). Its Scopus CiteScore is 3.1, quartile Q3. On 2-year citations it ranks #28 of 77 Scopus journals in Biochemistry (medical).
Advances in Biomarker Sciences and Technology published 42 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 88 research articles (2024–2026), authors are most often from India (52.8%), United States (7.6%) and China (7.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.